Ropes & Gray advised iTeos Therapeutics in the deal.
iTeos Therapeutics closed a collaboration with global healthcare leader GSK to co-develop and co-commercialize an anti-TIGIT monoclonal antibody called EOS-448, currently in Phase I development as a potential treatment for patients with cancer.
Under the terms of the collaboration agreement, iTeos will receive an upfront payment of $625 million. iTeos will be eligible to receive up to an additional $1.45 billion in milestone payments, should the EOS-448 program achieve certain development and commercial milestones.
Within the collaboration, GSK and iTeos will share responsibility and costs for the global development of EOS-448 and will jointly commercialize and equally split profits in the US. Outside of the US, GSK will receive an exclusive license for commercialization and iTeos will receive tiered royalty payments.
TIGIT is an immune checkpoint protein that is expressed on multiple immune cells, including T cells. The immune-oncology treatment is designed to deactivate a cancer tumor’s ability to evade the immune system.
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality.
The Ropes & Gray team was led by life sciences licensing partner Hannah Freeman (Picture) and included IP transactions partner David McIntosh, tax partner David Saltzman (all of Boston), antitrust partner Mike McFalls (Washington, D.C.), litigation & enforcement partner Ruchit Patel (London) and IP transactions associates Maria Colella and Ana Gomez-Palazzo (Boston).
Involved fees earner: Maria Colella – Ropes & Gray; Hannah Freeman – Ropes & Gray; Ana Gomez-Palazzo – Ropes & Gray; Michael McFalls – Ropes & Gray; David McIntosh – Ropes & Gray; Ruchit Patel – Ropes & Gray; David Saltzman – Ropes & Gray;
Law Firms: Ropes & Gray;
Clients: iTeos Therapeutics;